Steven Sun
Overview
Explore the profile of Steven Sun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weber H, Corson S, Li J, Mercier F, Roychoudhury S, Sailer M, et al.
Pharm Stat
. 2023 Oct;
23(1):91-106.
PMID: 37786317
Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the best overall response...
2.
Prabhu L, Martin M, Chen L, Demir O, Jin J, Huang X, et al.
Genes Dis
. 2023 Apr;
10(1):267-283.
PMID: 37013054
Market drugs, such as Food and Drug Administration (FDA) or European Medicines Agency (EMA)-approved drugs for specific indications provide opportunities for repurposing for newer therapeutics. This potentially saves resources invested...
3.
Johnson P, Balasubramanian S, Hodkinson B, Shreeve S, Sun S, Srinivasan S, et al.
Blood Adv
. 2023 Jan;
7(10):2008-2017.
PMID: 36696540
Diffuse large B-cell lymphoma (DLBCL), with high coexpression of BCL2 and MYC proteins (DE lymphoma), is considered an adverse prognostic indicator associated mostly with non-germinal center B-cell-like (non-GCB) DLBCL. BCL2/MYC...
4.
Zhang L, Burns N, Ji Z, Sun S, Deutscher S, Carson 3rd W, et al.
Nanomedicine
. 2022 Dec;
48:102642.
PMID: 36581256
Detection of cancer in its early stage is a challenging task for oncologists. Inflammatory breast cancer has symptoms that are similar to mastitis and can be mistaken for microbial infection....
5.
Burke G, Vinti L, Kabickova E, Beishuizen A, Tacyildiz N, Uyttebroeck A, et al.
Blood Adv
. 2022 Dec;
7(4):602-610.
PMID: 36541957
Part 1 results of the open-label, randomized, global phase 3 SPARKLE trial supported continued assessment of ibrutinib with either modified rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide,...
6.
Zhu J, Hong X, Song Y, Hodkinson B, Balasubramanian S, Wang S, et al.
EJHaem
. 2022 Dec;
3(4):1154-1164.
PMID: 36467814
In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (= 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine...
7.
Expression Patterns of microRNAs and Associated Target Genes in Ulcerated Primary Cutaneous Melanoma
DiVincenzo M, Schwarz E, Ren C, Barricklow Z, Moufawad M, Yu L, et al.
J Invest Dermatol
. 2022 Oct;
143(4):630-638.e3.
PMID: 36202232
Ulcerated cutaneous melanoma carries a poor prognosis, and the underlying biology driving its aggressive behavior is largely unexplored. MicroRNAs (miRs) are small, noncoding RNAs that inhibit the expression of specific...
8.
Freeman C, Pararajalingam P, Jin L, Balasubramanian S, Jiang A, Xu W, et al.
Leukemia
. 2022 Aug;
36(10):2479-2487.
PMID: 35963941
Mantle cell lymphoma (MCL) is a rare, incurable lymphoma subtype characterized by heterogeneous outcomes. To better understand the clinical behavior and response to treatment, predictive biomarkers are needed. Using residual...
9.
Sun S, Pithavala Y, Martini J, Chen J
J Clin Pharmacol
. 2022 Apr;
62(9):1170-1176.
PMID: 35373356
Lorlatinib is a third-generation, brain-penetrant anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) with robust intracranial activity in patients with ALK- or ROS1-positive non-small cell...
10.
Martin M, Mundade R, Hartley A, Jiang G, Jin J, Sun S, et al.
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269880
Since nuclear factor (NF) κB plays pivotal roles in inflammation and cancer, understanding its regulation holds great promise for disease therapy. Using the powerful validation-based insertional mutagenesis (VBIM) technique established...